/
LFCR
$4.96-$0.21 (-4.06%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$193.9M
38M shares
52-week range
$3.63 – $8.98
25% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.46%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-4.25
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $524.2M | $557.6M | $160.1M | $100.9M | $111.3M | $103.3M | $128.3M | $128.9M |
| Cost of revenue | $445.9M | $476.6M | $120.7M | $61.9M | $72.2M | $75.3M | $86.4M | $88.6M |
| Gross profit | $78.3M | $81.0M | $39.4M | $38.9M | $39.1M | $28.0M | $41.9M | $40.3M |
| Gross margin | 14.9% | 14.5% | 24.6% | 38.6% | 35.1% | 27.1% | 32.6% | 31.3% |
| R&D | $12.8M | $11.5M | $7.6M | $6.7M | $7.8M | $8.7M | $8.6M | $8.3M |
| Operating income | $11.8M | −$8.0M | −$25.9M | −$8.8M | −$11.8M | −$21.8M | −$8.8M | −$17.2M |
| EBITDA | $25.0M | $23.5M | −$7.2M | −$987.0K | $12.8M | −$33.2M | $35.6M | −$8.8M |
| Net income | $24.8M | $2.1M | −$38.2M | −$32.3M | −$116.7M | −$99.6M | $12.0M | −$38.7M |
| Net margin | 4.7% | 0.4% | -23.9% | -32.0% | -104.9% | -96.4% | 9.4% | -30.0% |
| EPS (diluted) | 0.89 | 0.07 | -1.31 | -1.12 | -3.97 | -3.32 | 0.33 | -1.27 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $122M | $-1.04 | $-1.07–$-1.00 | 2 |
| 2028 | $130M | $-0.98 | $-1.01–$-0.96 | 1 |
| 2029 | $150M | $-1.18 | $-1.21–$-1.15 | 1 |
| 2030 | $182M | $-0.65 | $-0.66–$-0.64 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Lifecore Biomedical, Inc. Common Stock
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
www.lifecore.com- Employees
- 382
- IPO / List date
- Feb 15, 1996
- HQ
- CHASKA, MN
Held by traders on TradeandTell
No one on the platform currently holds LFCR.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2024-06-30 | 11,000 | $56.4K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded LFCR yet.
